Search results
AstraZeneca posts mixed results from recent Imfinzi trials
ShareCast· 4 days agoAstraZeneca announced contrasting results from two phase three trials involving its immunotherapy...
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Zacks via Yahoo Finance UK· 24 hours agoThis Score examines things like projected and historical earnings, sales, and cash flow to find...
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Zacks via Yahoo Finance UK· 3 days agoData from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy...
AstraZeneca disappointed with failure of immunotherapy in early-stage lung cancer
Proactive Financial News· 4 days agoAstraZeneca PLC (LSE:AZN) shared some disappointing news on an advanced lung cancer trial of its...
Google Deepmind among nominees for ‘Nobel Prize of engineering’
CityAM via Yahoo Finance UK· 1 day agoAI-powered weather forecasting, innovative heat batteries and the rapid manufacturing scale-up of a...
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung...
Benzinga via Yahoo Finance UK· 4 days agoOn Tuesday, AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADJUVANT BR.31 Phase 3...
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
Zacks via Yahoo Finance UK· 1 day agoThis week, the FDA rejected Merck's MRK and AbbVie’s ABBV regulatory filings seeking approvals for...
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment
Reuters· 3 days agoAstraZeneca said the approval by China's National Medical Products Administration (NMPA) was based...
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers
Reuters via Yahoo Finance UK· 4 days agoImfinzi is a human monoclonal antibody, which works to block a tumour's ability to evade and dampen...
TOP NEWS: AstraZeneca details mixed findings from cancer drug trials
Morningstar· 4 days agoShares in AstraZeneca rose 0.6% to 12,548.00 pence on Tuesday morning. The Cambridge-based pharmaceutical company said Imfinzi met both its primary and secondary aims in a trial on sufferers of bladder cancer.